Tag Archives: Aricept

Alzheimer’s Disease Therapies

Current Therapies for Alzheimer’s Disease Because there is currently no cure for Alzheimer’s disease (), the primary goal of treatment remains the relief of cognitive, functional, and behavioral symptoms associated with the disease. Hence, current therapies aim to improve the quality of life for both Alzheimer’s disease patients and the caregivers who often must cope… Read More »

Alzheimer’s Therapy: Beta-Amyloid Aggregation Inhibitors

Overview. Drugs in development to inhibit beta-amyloid aggregation include Praecis Pharmaceuticals’ Apan (PPI-1019), a compound developed by Senexis in preclinical testing, and Hoffmann-La Roche’s CPHPC. PPI-1019 is in Phase I development and has been shown in animal models to increase Aβ-40 levels in the cerebrospinal fluid (CSF), suggesting that the drug promotes the clearance of… Read More »

Alzheimer’s Therapy: Acetylcholinesterase Inhibitors

Overview. Acetylcholinesterase inhibitors are the only drugs approved for the treatment of mild to moderate Alzheimer’s disease in the major markets. acetylcholinesterase inhibitors do not cure Alzheimer’s disease but do alleviate the cholinergic deficit observed in Alzheimer’s disease patients. Cognitive symptoms are occasionally improved but most often are only stabilized by the drugs (). Studies… Read More »

Information about Alzheimer’s Disease for Patients and Families

Alzheimer’s disease is the most common and well-known form of degenerative dementia. By definition, dementia is a syndrome, a cluster of symptoms, of impaired memory and cognition. Dementia is a cognitive disorder that impairs an individual’s memory and ability for reasoning, awareness, and judgment. Cognitive impairment in Alzheimer’s disease may involve disturbance of language (aphasia),… Read More »

Schizophrenia: Acetylcholinesterase Inhibitors

Three acetylcholinesterase inhibitors are on the market for the treatment of Alzheimer’s disease: Japan&Japan/Shire/Janssen’s galantamine (Reminyl), Eisai/Pfizer’s donepezil (Aricept), and Novartis’s rivastigmine (Exelon/Prometax). Clinical studies evaluating these agents in the treatment of the cognitive dysfunction and negative symptoms associated with schizophrenia have been performed, but only galantamine appears to be in commercial development for schizophrenia… Read More »

Chronic Illness: Current Therapies

The main goal of bipolar disorder drug treatment is to establish euthymia (stable mood with a persistent sense of well-being) without inducing mania or rapid cycling (i.e., four or more mood episodes in a 12-month period). For this reason, drug treatment usually consists of an agent or, more frequently, combinations of agents that exert both… Read More »

Views Of The Patient With Severe Dementia

A patient with severe dementia does not only suffer from a decreased ability to perform ADL, they are also often described as having reduced capability to communicate, reduced mobility, apraxia, agnosia, psychological and behavioural symptoms. This means that people in this stage of the disease are dependent on others to manage their daily life. There… Read More »

Environment And Behaviour

A frequent and often distressing complication related to dementia is the occurrence of behavioural and psychological symptoms in dementia (). These symptoms are described as manifestations of disrupted perceptions of reality with altered mood and distorted behaviour as expressed through anxiety, hallucinations and delusions, agitation and aggression such as physical or verbal outbursts, activity disturbances… Read More »

The place of drug treatment in psychiatry

It is difficult to overstate the central role that drug treatment plays in modern-day psychiatry. Psychiatric hospitals and community mental health team activities revolve around the various rituals of drug treatment. A United Kingdom survey of psychiatric hospitals found that 98-100% of inpatients were prescribed drugs and that most take several different ones at the… Read More »